Company intelligence / Profile preview

Domainex

Cambridge, England, United Kingdomdomainex.co.uk ↗

Ownership: Private
Development stage: Preclinical

Overview

Domainex provides integrated drug discovery services from target validation to preclinical candidate nomination. Its proprietary technologies accelerate the identification and optimization of drug candidates. The company has an internal pipeline focused on kinase inhibitors for inflammatory diseases and epigenetic modulators in oncology, both at the preclinical stage. It also supports numerous external programs through its CRO business.

Therapeutic areas: OncologyImmunologyOther
Modalities: small moleculesprotein-based assays (enabling technology)
Industry: Biotech

Partnerships

Collaborates with pharmaceutical companies, biotech firms, academic institutions, patient foundations globally through its service model.

Beyond the preview

Go deeper on Domainex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Domainex.

Explore the full profile